ArticleHaematologica2018
Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.Nature reviews. Nephrology · 2019Guideline
- Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation.Current oncology (Toronto, Ont.) · 2025Article
- Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression.Annals of hematology · 2024Observational
- Clonal hematopoiesis of indeterminate potential in patients with immunoglobulin light-chain AL amyloidosis.Blood advances · 2024Article
- Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.Nature communications · 2022Article
- Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.Pathology oncology research : POR · 2022Article
- Current Updates on the Management of AL Amyloidosis.Journal of hematology · 2021Review
- Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.Experimental hematology & oncology · 2021Review
- Comprehensive Review of AL amyloidosis: some practical recommendations.Blood cancer journal · 2021Review
- Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.Blood cancer journal · 2021Review
- Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.Blood cancer journal · 2021Article
- Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis.Therapeutic advances in hematology · 2021Review
- Future Perspectives.Hematology/oncology clinics of North America · 2020Review
- Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?International journal of hematology · 2020Article
- Review
- New developments in diagnosis, risk assessment and management in systemic amyloidosis.Blood reviews · 2020Review
- Cardiac amyloidosis presenting with recurrent ischaemic strokes.BMJ case reports · 2020Article
- Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses.Frontiers in pharmacology · 2020Review
- Approach to a patient with cardiac amyloidosis.Journal of geriatric cardiology : JGC · 2019Article
- Light chain lambda myeloma with fatal AL cardiac amyloidosis in a 21-year-old patient: A case report and review.Clinical case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.